疏风解毒胶囊辅助治疗社区获得性肺炎的系统评价与Meta分析
结果显示联合治疗可缩短发热、咳嗽、咳痰、肺部啰音、气短和胸痛缓解时间1-2天,不良事件轻微可控,无严重不良事件报告。
要点
- 疏风解毒胶囊联合抗生素或常规治疗可缩短发热、咳嗽等症状缓解时间约1-2天。
- 未报告严重不良事件,恶心发生率组间无显著差异。
- 证据质量多为中至极低,需更高质量RCT验证。
核心结论
- 现有证据提示加用疏风解毒胶囊可缩短社区获得性肺炎症状缓解时间1-2天。
- 不良事件轻微可控,无严重不良事件报告。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Scopus、Web of Science、CENTRAL、CNKI、VIP、CBM、Wanfang及试验注册平台至2022年3月。
- 两名评价员独立筛选文献、提取数据并评估偏倚风险,证据总体 certainty 为中至极低。
主要发现
- 与常规治疗相比,疏风解毒胶囊联合常规治疗缩短发热缓解时间(MD -1.20天,95%CI -1.73至-0.67;10项RCT;极低 certainty)。
- 缩短咳嗽缓解时间(MD -1.02天,95%CI -1.23至-0.81;9项RCT;中等 certainty)。
- 缩短咳痰缓解时间(MD -1.46天,95%CI -2.84至-0.08;6项RCT;极低 certainty)。
- 缩短肺部啰音缓解时间(MD -1.61天,95%CI -2.64至-0.59;8项RCT;低 certainty)。
- 缩短气短缓解时间(MD -2.80天,95%CI -2.88至-2.72;2项RCT;低 certainty)和胸痛缓解时间(MD -2.85天,95%CI -3.01至-2.69;1项RCT;低 certainty)。
关键数值与推荐
- 病原体清除率方面1项RCT显示无显著差异。
- 疏风解毒胶囊组恶心发生率为2.60%(5/192),常规组为1.04%(2/192),无显著差异。
- 未报告严重不良事件。
临床怎么用
- 社区获得性肺炎患者可在常规治疗基础上考虑加用疏风解毒胶囊以缩短症状缓解时间。
- 用药期间注意监测恶心等轻微不良事件,无需过度担忧严重不良事件。
局限性
- 纳入试验方法学质量有限,证据总体 certainty 为中至极低。
- 部分结局指标仅基于少量RCT,结果稳定性不足。
- 未来需设计良好的试验验证疗效及减少抗生素使用的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Shufeng Jiedu (SFJD) capsules can be used as adjunctive treatment for patients with community-acquired pneumonia, but the effectiveness and safety of SFJD are not clear. This review aims to evaluate the effectiveness and safety of SFJD based on randomized controlled trials (RCTs). Methods: A systematic review was conducted by searching PubMed, Embase, Scopus, Web of Science, CENTRAL, CNKI, VIP, CBM, Wanfang and trial registry platforms from their inception to March 2022. Two reviewers screened studies, extracted the data and assessed risk of bias independently. The data were pooled for meta-analysis or presented narratively. Results: Seventeen RCTs involving 1840 participants were included. All trials compared SFJD plus antibiotics to antibiotics, or combined with symptomatic treatment in both groups. The overall certainty of evidence was assessed as moderate to very low certainty. Compared with routine treatment (antibiotics alone or antibiotics plus symptomatic treatment), SFJD plus routine treatment showed beneficial effects in resolution of fever (MD -1.20 days, 95%CI -1.73 to -0.67; 10 RCTs; very low certainty), cough (MD -1.02 days, 95%CI -1.23 to -0.81; 9 RCTs; moderate certainty), phlegm (MD -1.46 days, 95%CI -2.84 to -0.08; 6 RCTs; very low certainty), pulmonary crepitations (MD -1.61 days, 95%CI -2.64 to -0.59; 8 RCTs; low certainty), shortness of breath (MD -2.80 days, 95%CI -2.88 to -2.72; 2 RCTs; low certainty) and chest pain (MD -2.85 days, 95%CI -3.01 to -2.69; 1 RCT; low certainty). There was no significant difference in pathogen clearance (1 RCT). No serious adverse events were reported, but 2.60% (5/192) patients reported nausea in the SFJD groups, 1.04% (2/192) participants in routine group, and no significant difference was identified. Conclusions: Current evidence suggests that adding SFJD may shorten the duration of symptom relief in community-acquired pneumonia for 1-2 days. The adverse events were minor and controllable, and no serious adverse events were reported. Well-reported trials and potential of reducing antibiotics were expected in the future studies.
引用
- Zhang XW, Xia RY, Gao JQ, et al. Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2022. PMID: 35860018. doi:10.3389/fphar.2022.923395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。